Literature DB >> 23182539

Pharmacodynamic modelling of intravenous antibiotic prophylaxis in elective colorectal surgery.

P Moine1, D N Fish.   

Abstract

Surgical-site infections are the leading cause of post-operative morbidity and mortality as well as increased costs following colorectal surgery. The purpose of this study was to evaluate different β-lactam antimicrobial dosing regimens currently used for prophylaxis in elective colorectal procedures with the aim of identifying optimal antibiotics and dosing regimens. Serum pharmacokinetic (PK) parameters specific to each drug for use in pharmacodynamic (PD) modelling were obtained from the published literature. Susceptibility data for Escherichia coli, Bacteroides fragilis and Staphylococcus aureus for use in modelling simulations were obtained from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Monte Carlo simulation was used to evaluate the influence of dose and dosing frequency of tested antibiotics to achieve a prophylaxis target fT>MIC (time during which the free drug concentration exceeds the pathogen minimum inhibitory concentration) of 100% for up to 4h. Ertapenem 1g, cefuroxime 1.5 g and cefazolin 2 g were the only antibiotic regimens that consistently yielded target fT>MIC of 100% for the entire 4-h post-dose interval and against all targeted organisms more than 90% of the time. In contrast, cefoxitin, cefotetan and ampicillin/sulbactam yielded very poor predicted PK/PD performances. In conclusion, this study demonstrates the value of, and need for, applied PD research in the area of surgical prophylaxis. Whether cefoxitin, cefotetan or ampicillin/sulbactam should continue to be advocated as first-line agents for prophylaxis during elective colorectal surgery, particularly at the standard doses currently being used, is debatable.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182539     DOI: 10.1016/j.ijantimicag.2012.09.017

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.

Authors:  XiangQing Song; MingHui Long
Journal:  Int J Clin Pharm       Date:  2018-08-16

2.  Antimicrobial Prophylaxis for Patients Undergoing Cardiac Surgery: Intraoperative Cefazolin Concentrations and Sternal Wound Infections.

Authors:  Sheryl A Zelenitsky; Divna Calic; Rakesh C Arora; Hilary P Grocott; Ted M Lakowski; Ryan Lillico; Robert E Ariano
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

3.  Pharmacokinetic and Pharmacodynamic Evaluation of a Weight-Based Dosing Regimen of Cefoxitin for Perioperative Surgical Prophylaxis in Obese and Morbidly Obese Patients.

Authors:  Pierre Moine; Scott W Mueller; Jonathan A Schoen; Kevin B Rothchild; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling.

Authors:  Eduardo Celia Palma; Nelson Guardiola Meinhardt; Airton Tetelbom Stein; Isabela Heineck; Maria Isabel Fischer; BibianaVerlindo de Araújo; Teresa Dalla Costa
Journal:  Pharm Res       Date:  2018-04-11       Impact factor: 4.200

5.  Target site antibiotic concentrations in orthopedic/trauma extremity surgery: is prophylactic cefazolin adequately dosed? A systematic review and meta-analysis.

Authors:  Fay R K Sanders; J Carel Goslings; Ron A A Mathôt; Tim Schepers
Journal:  Acta Orthop       Date:  2019-02-11       Impact factor: 3.717

6.  Wound infection following implant removal of foot, ankle, lower leg or patella; a protocol for a multicenter randomized controlled trial investigating the (cost-)effectiveness of 2 g of prophylactic cefazolin compared to placebo (WIFI-2 trial).

Authors:  Fay R K Sanders; Diederick Penning; Manouk Backes; Siem A Dingemans; Susan van Dieren; Anne M Eskes; J Carel Goslings; Peter Kloen; Ron A A Mathôt; Niels W L Schep; Ingrid J B Spijkerman; Tim Schepers
Journal:  BMC Surg       Date:  2021-02-01       Impact factor: 2.102

Review 7.  Review of Pure Endoscopic Full-Thickness Resection of the Upper Gastrointestinal Tract.

Authors:  Hirohito Mori; Hideki Kobara; Noriko Nishiyama; Shintaro Fujihara; Tsutomu Masaki
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.